Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients
Yuka Ohe,Sachio Fushida,Takahisa Yamaguchi,Jun Kinoshita,Hiroto Saito,Koichi Okamoto,Keishi Nakamura,Hidehiro Tajima,Itasu Ninomiya,Tetsuo Ohta
DOI: https://doi.org/10.2147/CMAR.S241069
2020-02-21
Cancer Management and Research
Abstract:Yuka Ohe, Sachio Fushida, Takahisa Yamaguchi, Jun Kinoshita, Hiroto Saito, Koichi Okamoto, Keishi Nakamura, Hidehiro Tajima, Itasu Ninomiya, Tetsuo Ohta Department of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Japan Correspondence: Sachio Fushida Department of Gastroenterological Surgery, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa 920-8641, Japan Tel +8176-265-2362 Email fushida@staff.kanazawa-u.ac.jp Introduction: Platelets are one factor promoting tumor development. Conversely, lymphocytes are one factor for immune protection. The peripheral blood platelets–lymphocyte ratio (PLR) is useful as an inflammation/immune indicator to predict postoperative recurrence and prognosis of a variety of malignancies. The peripheral blood neutrophil–lymphocyte ratio (NLR) has also been reported as a useful inflammation/immune indicator. However, there are few studies evaluating the relationship between these peripheral blood indicators and the effectiveness of chemotherapy. Thus, we examined these relationships in gastric cancer patients. Patients and Methods: Between 2005 and 2018, 41 gastric cancer patients treated with preoperative DCS therapy (docetaxel, cisplatin, and S-1) therapy followed by gastrectomy were evaluated. Data for peripheral blood tests prior to the initiation of chemotherapy were used. The effectiveness of chemotherapy was determined using Response Evaluation Criteria in Solid Tumors (RECIST) and the pathological response of primary lesions (Ef grade). The relationship between the blood test results and the effectiveness of chemotherapy was evaluated. Results: Each optimal cut-off value of peripheral inflammation/immune indicators was calculated through ROC curves. Although the pathological responder (Ef grade 2 or 3) revealed significantly better prognosis than the non-responder (Ef grade 0-1b), no relationship was found between responder according to RECIST and prognosis ( P =0.014, P =0.992). In univariate analysis, a low PLR (< 180, P =0.005), low NLR (< 2.6, P =0.019), high lymphocyte (≥ 1.43, P =0.019) and high PNI (≥ 40, P =0.032) were identified as prognostic markers, whereas PLR was the only marker correlated with pathological response ( P =0.031). Conclusion: PLR obtained prior to chemotherapy might be a useful indicator for predicting chemosensitivity owing to the simplicity of its procedure. Keywords: gastric cancer, preoperative chemotherapy, chemosensitivity, platelet-lymphocyte ratio
oncology